Table of contents
This is a summary of the European public assessment report (EPAR) for Vemlidy. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Vemlidy.
For practical information about using Vemlidy, patients should read the package leaflet or contact their doctor or pharmacist.
Vemlidy : EPAR - Summary for the public (PDF/78.83 KB)
First published: 10/03/2017
Last updated: 10/03/2017
Vemlidy : EPAR - Risk-management-plan summary (PDF/133.77 KB)
First published: 18/08/2021
Last updated: 24/10/2022
|Agency product number||
tenofovir alafenamide fumarate
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Gilead Sciences Ireland UC
|Date of issue of marketing authorisation valid throughout the European Union||
IDA Business & Technology Park
01/09/2022 Vemlidy - EMEA/H/C/004169 - II/0038
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Antivirals for systemic use
Vemlidy is indicated for the treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg).